THERAPY DOSSIER · th-dfec0d90c865

NIMoEsh (New Interacting Motif E shot), a JNK-inhibitory peptide

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Haemorrhage/shock
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30935978 ↗2019Reported benefit

The protection of New Interacting Motif E shot (NIMoEsh) in mice with collagenase-induced acute stage of intracerebral hemorrhage.

MouseHaemorrhage/shockUnspecifiedC57BL/6Male

Model: Collagenase-induced intracerebral haemorrhage, acute stage

NIMoEsh significantly inhibited JNK activity and reduced brain injury after intracerebral haemorrhage, improving inflammation, white matter damage and neuronal cell death.

Extraction: extract · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.

Loading the evidence…